论文部分内容阅读
目的探讨131I-肿瘤细胞核人鼠嵌合单抗(131I-chTNT)在脑胶质瘤瘤内放免治疗的疗效。方法选择56例经手术病理证实的脑胶质瘤病人作为治疗组,其中胶质母细胞瘤34例,星形细胞瘤22例。第1次手术20例,复发后再次手术36例。术中瘤腔内置入化疗囊,术后7 d囊内注131I-chTNT 1.48×109 Bq(40 mCi),15 d后重复注入1次。对照组24例,均经病理证实为复发性星形细胞瘤,采用卡莫司汀6.0 g静注1次/d,连用3 d;间隔45 d后,重复1个疗程。结果治疗组于末次注药后2个月复查MRI,随访期6～26个月,显效21例(37.5%),有效24例(42.8%),微效7例(12.5%),恶化4例(7.1%)。对照组末次用药后1个月复查MRI,随访期3～24个月,有效2例(8.3%),微效11例(45.8%),恶化11例(45.8%)。经2χ检验,治疗组与对照组间疗效差异有统计学意义(P<0.05)。结论131I-chTNT脑胶质瘤瘤内放免治疗临床疗效满意,优于其他类型的瘤内近距离放疗。
Objective To investigate the therapeutic effect of 131I-chimerism (131I-chTNT) on glioma in 131I-tumor cells. Methods Fifty-six patients with pathologically confirmed glioma were selected as the treatment group, including 34 cases of glioblastoma and 22 cases of astrocytoma. The first operation in 20 cases, 36 cases of recurrence after surgery. Chemotherapy balloon was placed intra-operatively in the tumor cavity, and 131I-chTNT 1.48 × 109 Bq (40 mCi) was injected intracranially 7 days after operation. The injection was repeated once 15 days later. The control group of 24 patients, all confirmed by pathology as recurrent astrocytoma, with Carmustine 6.0 g intravenously 1 / d, once every 3 d; interval 45 d, repeat one course of treatment. Results In the treatment group, the MRI was reviewed two months after the last injection. The follow - up period was 6 to 26 months, 21 (37.5%) were effective, 24 (42.8%) were effective, 7 (12.5% (7.1%). MRI was reviewed one month after the last administration in the control group, 2 cases (8.3%) were effective in 3-24 months follow-up period, 11 cases (45.8%) were poor and 11 cases (45.8%) were deteriorated. The 2χ test, the treatment group and control group, the difference was statistically significant (P <0.05). Conclusions 131I-chTNT glioma tumor release therapy is satisfactory in clinical efficacy, superior to other types of intratumoral brachytherapy.